Get started
XINTELA ABXX

XINTELA AB

0.384SEKD
−0.009−2.29%
At close at May 30, 15:29 GMT
SEK
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

XINT fundamentals

Key facts

Market capitalization‪255.67 M‬SEK
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.07SEK
Founded2009
Employees (FY)—
CEOEvy Lundgren-Åkerlund
Websitexintela.se
About

Xintela AB is a biomedical company. It engages in the business of developing medical products in stem cell therapy and targeted cancer therapy based on the cell surface marker integrin a10ß1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The company was founded by Evy Lundgren-Åkerlund and Rickard Mosell in 2009 and is headquartered in Lund, Sweden.

Ownership
‪‪665.80 M‬‬
Free Float shares
‪‪373.97 M‬‬ (56.17%)
Closely held shares
‪‪291.83 M‬‬ (43.83%)
Free Float shares
‪‪373.97 M‬‬ (56.17%)
Closely held shares
‪‪291.83 M‬‬ (43.83%)
Capital structure
Market cap
‪‪255.67 M‬‬
Cash & equivalents
‪‪6.40 M‬‬
Enterprise value
‪‪249.27 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪255.67 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
64.51x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
64.51x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪120.00‬
‪240.00‬
‪360.00‬
‪480.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−280,250.00%‬
‪−210,250.00%‬
‪−140,250.00%‬
‪−70,250.00%‬
‪−250.00%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
‪‪4.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
‪‪4.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
‪‪4.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Medical Products within Stem Cell Therapy and Targeted Cancer Therapy
By country
Period: 2024
Sweden

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
Estimate
Earnings
Next:Aug 29, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.12‬
‪−0.09‬
‪−0.06‬
‪−0.03‬
‪0.00‬
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
XINT has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−51.00 M‬‬
‪‪−34.00 M‬‬
‪‪−17.00 M‬‬
‪0.00‬
‪‪17.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪8.00 M‬‬
‪‪16.00 M‬‬
‪‪24.00 M‬‬
‪‪32.00 M‬‬
Assets
Liabilities